The effect of intravitreal pharmaceutical inhibition of vascular endothelial growth factor (VEGF) on macular edema and retinal vascular leakage secondary to CRVO is profound, supporting that relapse of CRVO is driven by vessel wall frailty rather than recurrent thrombosis of the central retinal vein. This evidence concerns the gene VEGFA and macular retinal edema.